Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2006
Reporting Period: The filing references financial results for the quarter ended September 30, 2006, and provides updated guidance for the fiscal year ending December 31, 2006.
Key Financial Metrics
This filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reported period. It serves as a notification of a variance in the annual revenue budget and references a separate Form 10-Q for detailed financial statements.
- Updated Fiscal Year 2006 Revenue Estimate: $355,000
- Original Budgeted Revenue (Feb 2006): $313,000
- Currency Exchange Rate (Supplementary): 117.90 Japanese Yen per U.S. Dollar (as of September 30, 2006)
Material Changes
The primary material change disclosed is an upward revision to the estimated revenue for the fiscal year ending December 31, 2006. The estimate increased from the previously budgeted amount of $313,000 to $355,000. This variance was reported to the Osaka Securities Exchange (OSE) via a "Kessan Tanshin" and a press release.
Guidance, Outlook, and Risks
Guidance Update: Management has revised its full-year revenue guidance upward by $42,000 based on the latest operational data.
Forward-Looking Statements: The report contains forward-looking statements regarding future activities and developments. These are based on management's assumptions and historical trends.
Risks: Actual results may differ materially from implied or expressed forward-looking statements due to various assumptions, risks, and uncertainties beyond the Company's control. Investors are directed to the Form 10-Q filed on November 9, 2006, for a detailed discussion of these factors.
Investor Verification Checklist
- Verify the detailed financial results for the quarter ended September 30, 2006, in the Form 10-Q filed on November 9, 2006.
- Confirm the specific drivers behind the $42,000 increase in the fiscal year 2006 revenue estimate.
- Review the "Kessan Tanshin" filed with the Osaka Securities Exchange for supplementary financial statements denominated in Japanese Yen.
- Assess the risks and uncertainties outlined in the Form 10-Q that could impact the revised revenue guidance.